iGlarLixi Safe and Effective in Inadequately Controlled T2D
A once-daily injectable therapy of a fixed-ratio combination of insulin glargine and lixisenatide improved glycemic control, with low rates of hypoglycemia, in people with T2D in a real-world setting.